Piper Sandler Reiterates Overweight on Kronos Bio, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Kronos Bio (NASDAQ:KRON) and maintained a price target of $6.
October 08, 2024 | 2:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler's analyst Edward Tenthoff has reiterated an Overweight rating for Kronos Bio, maintaining a $6 price target. This suggests confidence in the company's potential for growth.
The reiteration of an Overweight rating and a maintained price target of $6 by a reputable analyst suggests a positive outlook for Kronos Bio. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100